A Phase I, First-in-Human, Healthy Volunteer Study to Investigate the Safety, Tolerability, and Pharmacokinetics of CVN424, a Novel G Protein-Coupled Receptor 6 Inverse Agonist for Parkinson’s Disease\textsuperscript{S}

David H. Margolin, Nicola L. Brice, Antonia M. Davidson,\textsuperscript{1} Kim L. Matthews, and Mark B. L. Carlton

Cerevance, Inc., Boston, Massachusetts (D.H.M.); Cerevance, Ltd., Cambridge, United Kingdom (N.L.B., K.L.M., M.B.L.C.); and Development, LP, Austin, Texas (A.M.D., P.P.D.)

Received July 13, 2021; accepted January 20, 2022

ABSTRACT
CVN424 is a novel small molecule and first-in-class candidate therapeutic to selectively modulate GPR6, an orphan G-protein coupled receptor. Expression of GPR6 is largely confined to the subset of striatal projection neurons that give rise to the indirect (striatopallidal) pathway, important in the control of movement. CVN424 improves motor function in preclinical animal models of Parkinson’s disease. Here, we report results of a phase 1, first-in-human study investigating the safety, tolerability, and pharmacokinetics of CVN424 in healthy volunteers. The study (NCT03657030) was randomized, double-blind, and placebo controlled. CVN424 was orally administered in ascending doses to successive cohorts as inpatients in a clinical research unit. Single doses ranged from 1 mg to 225 mg, and repeated (7 day) daily doses were 25, 75, or 150 mg. CVN424 peak plasma concentrations were reached within 2 h post-dose in the fasted state and increased with increasing dose. Dosing after a standardized high-fat meal reduced and delayed the peak plasma concentration, but total plasma exposure was similar. Mean terminal half-life ranged from 30 to 41 h. CVN424 was generally well tolerated: no serious or severe adverse effects were observed, and there were no clinically significant changes in vital signs or laboratory parameters. We conclude that CVN424, a nondopaminergic compound that modulates a novel therapeutic target, was safe and well tolerated. A phase 2 study in patients with Parkinson’s disease is underway.

SIGNIFICANCE STATEMENT
This is the first-in-human clinical study of a first-in-class candidate therapeutic. CVN424 modulates a novel drug target, GPR6, which is selectively expressed in a pathway in the brain that has been implicated in the motor dysfunction of patients with Parkinson’s disease. This study paves the way for investigating this novel mechanism of action in patients with Parkinson’s disease.

Introduction

The ability to pharmacologically modulate specific cell types and circuits offers great promise for development of new therapies to improve the management of Parkinson’s disease and other neurologic disorders (Fishell and Heintz, 2013). Parkinson’s disease patients commonly experience lapses in symptom relief (e.g., motor fluctuations) despite treatment with standard-of-care dopaminergic medications, and dosage increases intended to overcome those episodes are often limited by side effects, notably drug-induced dyskinesia.

Parkinson’s disease motor symptoms result from degeneration of dopamine-producing neurons of the nigrostriatal pathway and the consequent impact on dopamine-receptive striatal neurons and their efferent circuits. There are two major types of dopamine-receptive neurons in the striatum, which differ in the type of dopamine receptor they express and that give rise to separate efferent pathways. Medium spiny neurons that express dopamine D1 receptors give rise to the striatonigral “direct” pathway, whose activity normally facilitates movement but can also drive the involuntary movements of levodopa-induced dyskinesia (Ryan et al., 2018). Medium spiny neurons that express D2 receptors give rise to the striatopallidal “indirect” pathway, whose activity inhibits movement. Normally, dopamine acting via these D2 receptors lowers the

\textsuperscript{S}This article has supplemental material available at jpet.aspetjournals.org.

ABBREVIATIONS: AUC, area under the (plasma concentration–time) curve; AUC\textsubscript{ss}, area under the plasma concentration-time curve from time 0 to time \(t\); AUC\textsubscript{tau}, area under the plasma concentration-time curve during a dosing interval \(\tau\); CL/F, apparent total clearance of the drug from plasma (volume/time); C\textsubscript{min}, minimum observed plasma concentration; MAD, multiple ascending dose; PK, pharmacokinetic; R\textsubscript{AC}, accumulation ratio; SAD, single ascending dose; ss, steady state; TEAE, treatment-emergent adverse effect; T\textsubscript{max}, time of observed maximum plasma concentration; V/F, apparent volume of distribution during terminal phase.

\textsuperscript{1}Current affiliation: IQVIA Biotech, Morrisville, NC.

\textsuperscript{2}dx.doi.org/10.1124/jpet.121.000842.

\textsuperscript{3}This study was sponsored by Cerevance, Inc. D.H.M., N.L.B., K.L.M. and M.B.L.C. are full-time employees of Cerevance.

No author has any further actual or perceived conflict of interest with the contents of this article.

\textsuperscript{4}dx.doi.org/10.1124/jpet.121.000842.
neuronal level of 3′-5′-cyclic adenosine monophosphate (cAMP), facilitating movement by reducing neuronal activity in these striatal neurons and thus lessening the motor-inhibitory influence of the indirect pathway. Conversely, under the pathologic condition of dopamine depletion in Parkinson’s disease, the indirect pathway becomes hyperactive (DeLong & Wichmann, 2015) and contributes to bradykinesia and “freezing” of gait.

CVN424 is a potent and selective inverse agonist of GPR6, an orphan G-protein coupled receptor that is selectively expressed by the D2 receptor-positive neurons of the indirect pathway (Heiman et al., 2008). Expression of GPR6 is very low or absent in D1 receptor-positive neurons of the direct pathway and in other central nervous system regions and peripheral tissues (Morales et al., 2018) (Brice et al., 2021).

Since GPR6 is a Gαs-coupled receptor with high constitutive activity (Uhlenbrock et al., 2002), it normally increases cAMP and thereby activates the indirect pathway, in opposition to the inhibitory effect of the Gαi-coupled D2 receptors. CVN424 suppresses this constitutive activity, reducing cellular cAMP levels (Brice et al., 2021)(Sun et al., 2021) and potentially attenuating the pathologic hyperactivity of the indirect pathway seen in Parkinson’s patients (Fig. 1). Thus, CVN424 is predicted to mimic the salutary effect of dopaminemergen- ing on the indirect pathway but without concurrent activation of the direct pathway. CVN424 should thereby facilitate voluntary movement without exacerbating levodopa-induced dyskinesia, and thus has therapeutic potential in Parkinson’s disease as a monotherapy or as an adjunct to levodopa.

Preclinical testing of CVN424 included an extensive panel of pharmacology studies conducted in vitro and in vivo in rodents (Brice et al., 2021). These findings established that CVN424 was orally bioavailable and central nervous system penetrant. Importantly, CVN424 was effective at enhancing motor function in Parkinson’s disease preclinical models, such as the 6-hydroxydopamine lesion model in rodents (Brice et al., 2021), supporting the GPR6 inverse agonist therapeutic hypothesis.

Based on these data, a first-in-human trial was conducted to investigate the safety, tolerability, and pharmacokinetics of CVN424 in healthy subjects.

**Materials and Methods**

**Study Design.** The study was conducted at the Clinical Research Unit of PPD Development, LP, in Austin, TX, in compliance with the ethical principles of the Declaration of Helsinki, the Good Clinical Practice Guidelines of the International Conference on Harmonization, and local laws and regulations. This study was approved by the investigator’s Institutional Review Board. All the subjects were given detailed written and oral information about the study, and written informed consent was obtained before screening for eligibility. This study was registered at ClinicalTrials.gov (https://clinicaltrials.gov/ct2/show/NCT03657030).

This was a first-in-human, randomized, double-blinded, placebo-controlled single- and multiple-dose dose escalation study in healthy subjects. Each cohort consisted of 8 subjects randomized (3:1) to receive CVN424 or placebo under overnight fasted conditions. In the single ascending dose (SAD) portion of the study, 40 healthy male or female subjects, ages 18 to 50 years, were enrolled and randomized into 1 of 5 ascending dose cohorts (designated S1 through S5) to receive 1, 5, 25, 75, or 225 mg of CVN424 or placebo. In each single-dose cohort, 2 sentinel subjects (1 subject receiving CVN424 and the other placebo) were dosed first; the remaining 6 subjects of each cohort could be dosed after blinded review of 24-hour post-dose safety and tolerability data provided that the adverse event profile of CVN424 in the first 2 subjects was considered acceptable. For the multiple ascending dose (MAD) portion of the study, 24 subjects were enrolled in 1 of 3 ascending multiple-dose cohorts (designated M1 through M3) and randomized to receive 7 daily doses of 25, 75, or 150 mg of CVN424 or placebo. Dose escalations occurred after a blinded review of all available safety, tolerability, clinical laboratory results, and available pharmacokinetic (PK) data, including at least 72-hour post-dose follow-up of the most recent cohort.

Subjects for all cohorts were admitted to the clinical research unit 1 day prior to dosing and remained in the unit through at least 48 hours after their last dose for safety and PK assessments. The total confinement period was 4 or 9 nights for single- and multiple-dose cohorts, respectively. Outpatient or telephone follow-up assessments for single- and multiple-dose cohorts, respectively, occurred on approximately days 8 and 14 or days 10, 14, and 21.

The effect of food on bioavailability of CVN424 was assessed according to United States Food and Drug Administration Guidance for Industry, 2002. After the safety of a single dose of 5 mg administered in a fasted state had been assessed, the same subjects returned to the clinic (no sooner than 14 days after their prior dose) and received the same dose as before, administered after ingesting a standardized high-fat high-calorie breakfast. Subjects finished the entire content of their breakfast within 25 minutes and received investigational product 30 minutes (±5 minutes) after beginning the meal. Sentinel dosing was not required for subjects returning to the clinic for the fed regimen.

**Study Drug.** Aqueous suspensions of CVN424 contained 200 mg of hydroxypropyl methylcellulose, 50 mg of Tween-80, and 10 ml of water. Placebo contained the same ingredients but omitted active drug.

Applying a 20-fold safety margin below the human-equivalent dose corresponding to the no-observed-adverse-effect level from nonclinical toxicology studies, the maximum recommended starting dose for this first-in-human study per Food and Drug Administration guidance was 0.8 mg/kg, or 48 mg for a 60-kg subject. However, based on preclinical data, that dosage was predicted to yield up to 98% receptor occupancy of GPR6 sites in the brain. To be conservative, the starting dosage for the SAD was set at 1 mg, with an expected peak receptor occupancy of 58%.

**Subjects.** Eligible subjects were healthy male or female adult volunteers between 18 and 50 years of age, weighing at least 45 kg with a body mass index between 18 and 30 kg/m². Subjects were excluded at screening if they had out-of-range vital signs, clinically significant abnormalities on standard clinical laboratory testing or electrocardiogram, a positive urine result for cotinine or drugs of abuse, or had evi- dence of any disorder or other abnormality that might have impacted the ability of the subject to participate or potentially confounded the study results. Subjects agreed to abide by the study’s contraceptive requirements. (For eligibility criteria see Supplemental Material.)

**PK Assessments.** In the SAD cohorts, blood samples were obtained for PK analyses on day 1 pre-dose and serially through 72 hours post-dose. In the MAD cohorts, blood samples were collected for PK analyses on day 1 pre-dose and serially through 24 hours post-dose (i.e., day 2 pre-dose), pre-dose on days 3, 4, 5, and 6, and on day 7 pre-dose and serially through 72 hours post-dose. Plasma obtained after centrifugation was stored frozen at -70°C until analysis.

Plasma concentrations of CVN424 were quantitated using a validated assay based on liquid chromatography coupled with tandem mass spectrometry (Frontage Laboratories, Inc.; Exton, PA). The assay has a dynamic range of 0.100–100 ng/mL to extend the range, high-concentration samples were retested after dilution.

The following PK parameters were calculated for CVN424 from plasma concentration and actual time data for each subject by non-compartmental analysis using Phoenix WinNonlin (Certara LP, Princeton, NJ) Version 8.0: area under the concentration-time curve from time 0 to 24 hours (AUCt), from time 0 to time of the last quantifiable concentration (AUCq), from time 0 to infinity (AUC∞) and during a dosing interval (AUCint for Day 7 in multiple-dose cohorts), time
to the observed maximum plasma concentration (t<sub>max</sub>), the maximum observed plasma concentration after a single dose (C<sub>max</sub>) and at steady state (C<sub>max,ss</sub>), the minimum plasma concentration at steady state (C<sub>min,ss</sub>), apparent clearance CL/F, apparent volume (V<sub>A</sub>/F) and terminal half-life (t<sub>1/2z</sub>). Accumulation ratios based on AUC (Rac(AUC)) and C<sub>max</sub> (Rac(Cmax)) and dose-normalized AUCs, C<sub>max</sub>, and C<sub>max,ss</sub> were also calculated.

The PK parameters were summarized by treatment using summary statistics. Approximate attainment of steady state was visually assessed by plotting mean trough concentrations.

To evaluate dose proportionality, a power model was fitted to describe the relationship between Y (C<sub>max</sub>, AUC<sub>24</sub>, AUC<sub>τ</sub>, and AUC<sub>τ</sub> for single-dose cohorts and C<sub>max,ss</sub>, AUC<sub>24</sub>, AUC<sub>τ</sub>, and AUC<sub>τ</sub> for multiple-dose cohorts) and X (dose) using the least-squares linear regression model [ln(Y) = ln(a) + β × ln(X)]. Dose proportionality was concluded if the 90% confidence interval (CI) of the slope β lies entirely within [1 + ln(0.8) / ln(τ), 1 + ln(1.25) / ln(τ)], where τ is a ratio that describes the dose range and was defined as the ratio of highest dose/lowest dose (Smith et al., 2000).

To evaluate the effect of food on PK of CVN424 in suspension formulation, a linear mixed-effect model (SAS PROC MIXED) with treatment as a fixed effect and measurements within subject as repeated measures was fitted to the natural log-transformed PK parameters C<sub>max</sub>, AUC<sub>24</sub>, AUC<sub>τ</sub>, AUC<sub>τ</sub>, and for use in estimation of effects and construction of CIs for SAD cohort S2 Fed compared with SAD cohort S2 Fasted. Point estimates and 90% CIs for differences on the log scale were exponentiated to obtain estimates for the ratios of geometric means and respective 90% CIs on the original scale.

**Safety Assessment.** The study’s primary objective was to characterize in healthy subjects the safety and tolerability profile of escalating dose levels of a CVN424 suspension when administered as a single oral dose or daily oral doses for 7 days. Safety parameters included adverse events, vital sign measurements, physical examinations, clinical laboratory results, electrocardiographs (ECG), and assessment of suicidal ideation and behavior. Blood and urine samples were analyzed using hematology, coagulation, serum chemistry, urinalysis, and drug screen test panels. Additionally, serum prolactin and thyrotropin levels were monitored.

For single-dose cohorts, vital signs (oral temperature, respiration, pulse, and blood pressure) were obtained at screening and at inpatient check-in, Day 1 pre-dose, at 1, 2, 4, 6, 8, and 12 hours post-dose, then every 12 hours through 72 hours post-dose, at Outpatient Visit (Day 8) or Early Termination (if applicable), and as appropriate at follow-up (Day 14 ±2 days)). Triplicate orthostatic vital signs (blood pressure and heart rate) were recorded at baseline (inpatient check-in) 15 minutes apart. For multiple-dose cohorts, vital signs (oral temperature, respiration, pulse, and blood pressure) were obtained at screening and at inpatient check-in, on days Day 1 pre-dose and at 1,
2, 4, 6, 8, and 12 hours post-dose, on days 2 through 6 pre-dose and 12 hours post-dose, and in the morning on days 8 and 9 (24 and 36 hours post-dose, respectively). Triplicate orthostatic vital signs (blood pressure and heart rate) were recorded at baseline (inpatient check-in) 15 minutes apart.

**Statistical Analyses.** The safety set included all subjects who were enrolled and received study drug. The safety set was used for demographic, baseline characteristics, and safety summaries. The PK set included all subjects who received study drug and had at least 1 measurable plasma concentration.

Medical history and adverse events were coded using the Medical Dictionary for Regulatory Activities (Medical Dictionary for Regulatory Activities; Version 21.0); adverse events were coded by system organ class and preferred term. At each level of subject summarization, a subject was counted once if the subject reported one or more events. For the pooled treatment groups, subjects in the fed/fasted cohort (CVN424 5 mg or matching placebo) were counted once if the subject reported one or more events in either the fasted or fed treatment period. Concomitant medications were coded using World Health Organization Drug Dictionary, Version March 2018. The Statistical Analysis Plan was pre-specified. Statistical analyses were performed using SAS Version 9.3 (SAS Institute, Cary, NC). For categorical variables, number of subjects and percentages (rounded to 1 decimal place) were reported. Continuous variables were summarized using descriptive statistics and Kenward-Rogers degrees of freedom were specified for the use in estimation of the effects of CVN424 on body weight. The estimated least squares means and standard error were presented for each treatment at each post-baseline visit. The estimated mean difference between each CVN424 dose cohort and the corresponding pooled placebo group along with the standard error, 90% CI, and the 2-sided *P* value were presented at each post-baseline visit.

### Results

**Subjects.** A total of 64 subjects were enrolled, 48 received CVN424 (30 in the SAD cohorts and 18 in the MAD cohorts), and 16 received placebo (10 in the SAD cohorts and 6 in the MAD cohorts). One MAD subject who received a 75-mg dose of CVN424 discontinued early because of an adverse event of

<table>
<thead>
<tr>
<th>Parameter (unit)</th>
<th>CVN424</th>
<th>Placebo* (N = 6)</th>
<th>1 mg (N = 6)</th>
<th>5 mg (N = 6)</th>
<th>25 mg (N = 6)</th>
<th>50 mg (N = 6)</th>
<th>100 mg (N = 6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td></td>
<td>34.5 (7.7)</td>
<td>36.8 (8.9)</td>
<td>31.7 (8.1)</td>
<td>38.0 (7.87)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female, No. (%)</td>
<td></td>
<td>1 (16.7)</td>
<td>2 (33.3)</td>
<td>0</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male, No. (%)</td>
<td></td>
<td>5 (83.3)</td>
<td>4 (66.7)</td>
<td>6 (100.0)</td>
<td>6 (100.0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Race, No. (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td></td>
<td>2 (33.3)</td>
<td>4 (66.7)</td>
<td>5 (83.3)</td>
<td>3 (50.0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Black or African American</td>
<td></td>
<td>0</td>
<td>0</td>
<td>1 (16.7)</td>
<td>2 (33.3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>American Indian or Alaska Native</td>
<td></td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethnicity, No. (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hispanic or Latino</td>
<td></td>
<td>2 (33.3)</td>
<td>1 (16.7)</td>
<td>2 (33.3)</td>
<td>3 (50.0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Not Hispanic or Latino</td>
<td></td>
<td>4 (66.7)</td>
<td>2 (33.3)</td>
<td>4 (66.7)</td>
<td>4 (66.7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Height (cm)</td>
<td></td>
<td>171.6 (9.7)</td>
<td>173.0 (8.7)</td>
<td>174.7 (5.5)</td>
<td>175.8 (5.0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weight (kg)</td>
<td></td>
<td>78.1 (9.4)</td>
<td>84.0 (9.7)</td>
<td>83.0 (7.3)</td>
<td>83.9 (9.2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td></td>
<td>26.9 (2.1)</td>
<td>28.0 (1.1)</td>
<td>27.2 (1.9)</td>
<td>27.1 (1.7)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*No., number.

Subjects who received placebo were pooled across single-dose cohorts and similarly for multiple-dose cohorts.

<table>
<thead>
<tr>
<th>Parameter (unit)</th>
<th>CVN424</th>
<th>Placebo* (N = 10)</th>
<th>1 mg (N = 6)</th>
<th>5 mg (N = 6)</th>
<th>25 mg (N = 6)</th>
<th>75 mg (N = 10)</th>
<th>225 mg (N = 6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td></td>
<td>38.0 (10.1)</td>
<td>31.3 (7.8)</td>
<td>36.5 (9.8)</td>
<td>35.3 (8.2)</td>
<td>34.2 (7.1)</td>
<td>30.3 (8.0)</td>
</tr>
<tr>
<td>Female, No. (%)</td>
<td></td>
<td>3 (30.0)</td>
<td>2 (33.3)</td>
<td>2 (33.3)</td>
<td>2 (33.3)</td>
<td>0</td>
<td>1 (16.7)</td>
</tr>
<tr>
<td>Male, No. (%)</td>
<td></td>
<td>7 (70.0)</td>
<td>4 (66.7)</td>
<td>4 (66.7)</td>
<td>4 (66.7)</td>
<td>6 (100.0)</td>
<td>5 (83.3)</td>
</tr>
<tr>
<td>Race, No. (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td></td>
<td>9 (90.0)</td>
<td>4 (66.7)</td>
<td>5 (83.3)</td>
<td>3 (50.0)</td>
<td>5 (83.3)</td>
<td>4 (66.7)</td>
</tr>
<tr>
<td>Black or African American</td>
<td></td>
<td>1 (10.0)</td>
<td>2 (33.3)</td>
<td>0</td>
<td>3 (50.0)</td>
<td>1 (16.7)</td>
<td>2 (33.3)</td>
</tr>
<tr>
<td>American Indian or Alaska Native</td>
<td></td>
<td>0</td>
<td>0</td>
<td>1 (16.7)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Ethnicity, No. (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hispanic or Latino</td>
<td></td>
<td>6 (60.0)</td>
<td>1 (16.7)</td>
<td>4 (66.7)</td>
<td>2 (33.3)</td>
<td>2 (33.3)</td>
<td>3 (50.0)</td>
</tr>
<tr>
<td>Not Hispanic or Latino</td>
<td></td>
<td>4 (40.0)</td>
<td>5 (83.3)</td>
<td>2 (33.3)</td>
<td>4 (66.7)</td>
<td>4 (66.7)</td>
<td>3 (50.0)</td>
</tr>
<tr>
<td>Height (cm)</td>
<td></td>
<td>170.0 (10.4)</td>
<td>176.0 (12.3)</td>
<td>167.3 (9.0)</td>
<td>169.5 (9.9)</td>
<td>175.4 (7.1)</td>
<td>169.3 (7.5)</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td></td>
<td>75.7 (11.9)</td>
<td>78.1 (12.2)</td>
<td>72.6 (8.1)</td>
<td>72.0 (8.2)</td>
<td>75.6 (3.9)</td>
<td>73.6 (7.5)</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td></td>
<td>26.1 (2.6)</td>
<td>25.2 (2.5)</td>
<td>25.9 (1.9)</td>
<td>25.1 (2.8)</td>
<td>24.7 (2.1)</td>
<td>25.7 (2.4)</td>
</tr>
</tbody>
</table>

Values are mean (s.d.) unless otherwise noted.
dysphagia; all other subjects completed the study as per protocol. The demographic characteristics of the enrolled subjects are summarized in Table 1.

**Pharmacokinetics.** The mean plasma concentration-time profiles of CVN424 in the SAD and MAD cohorts are presented in Fig. 2.
Following administration of a single dose of CVN424 oral suspension in a fasted state, mean plasma CVN424 concentrations (Table 2) increased in a similar fashion for all dose levels, reaching a peak within 2 hours post-dose. Mean plasma CVN424 concentrations declined with a multiphasic elimination and showed a similar trend across all dose levels. Mean plasma CVN424 concentrations were detectable throughout 72 hours of post-dose sampling in all dosed subjects. Following administration of a single dose (5 mg) of CVN424 oral suspension under fed state, mean plasma CVN424 concentrations were slower to reach the peak level post-dose than in the fasted state, and the peak plasma concentration was lower.

Following single-dose oral administration of 1 mg to 225 mg of CVN424 under fasted conditions, mean peak plasma CVN424 concentrations declined with a multiphasic elimination and showed a similar trend across all dose levels. Mean plasma CVN424 concentrations were detectable throughout 72 hours of post-dose sampling in all dosed subjects. Following administration of a single dose (5 mg) of CVN424 oral suspension under fed state, mean plasma CVN424 concentrations were slower to reach the peak level post-dose than in the fasted state, and the peak plasma concentration was lower.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Treatment</th>
<th>1 mg (N = 6)</th>
<th>5 mg Fasted (N = 6)</th>
<th>5 mg Fed (N = 6)</th>
<th>25 mg (N = 6)</th>
<th>75 mg (N = 6)</th>
<th>225 mg (N = 6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cmax (ng/mL)</td>
<td>11.11 (31.1)</td>
<td>44.03 (9.3)</td>
<td>29.43 (14.3)</td>
<td>206.8 (25.6)</td>
<td>386.0 (13.3)</td>
<td>682.3 (39.7)</td>
<td></td>
</tr>
<tr>
<td>tmax (h)</td>
<td>1.500 (1.00, 1.52)</td>
<td>1.517 (1.50, 3.00)</td>
<td>3.000 (1.50, 5.00)</td>
<td>1.500 (1.50, 2.00)</td>
<td>2.000 (1.50, 2.00)</td>
<td>1.500 (1.00, 3.00)</td>
<td></td>
</tr>
<tr>
<td>AUC24 (h*ng/mL)</td>
<td>75.89 (23.9)</td>
<td>325.3 (9.7)</td>
<td>344.6 (14.1)</td>
<td>1608 (15.3)</td>
<td>4076 (21.8)</td>
<td>7511 (21.2)</td>
<td></td>
</tr>
<tr>
<td>AUCb (h*ng/mL)</td>
<td>124.8 (25.9)</td>
<td>554.6 (9.5)</td>
<td>635.0 (16.3)</td>
<td>2613 (18.4)</td>
<td>7134 (32.2)</td>
<td>17950 (19.9)</td>
<td></td>
</tr>
<tr>
<td>AUCc (h*ng/mL)</td>
<td>169.5 (33.2)</td>
<td>706.0 (19.9)</td>
<td>859.7 (29.2)</td>
<td>3323 (35.3)</td>
<td>8797 (41.6)</td>
<td>24720 (27.1)</td>
<td></td>
</tr>
<tr>
<td>t1/2 (h)</td>
<td>39.4 (32.6)</td>
<td>35.9 (34.8)</td>
<td>36.7 (40.4)</td>
<td>32.0 (50.4)</td>
<td>29.6 (21.2)</td>
<td>41.6 (12.8)</td>
<td></td>
</tr>
<tr>
<td>k (1/h)</td>
<td>0.0198 (41.1)</td>
<td>0.0214 (36.5)</td>
<td>0.0214 (37.0)</td>
<td>0.0262 (42.7)</td>
<td>0.0243 (20.7)</td>
<td>0.0169 (12.3)</td>
<td></td>
</tr>
<tr>
<td>CL/F (L/h)</td>
<td>6.067 (40.9)</td>
<td>7.320 (20.5)</td>
<td>6.247 (30.1)</td>
<td>8.177 (28.3)</td>
<td>9.622 (34.7)</td>
<td>9.605 (29.4)</td>
<td></td>
</tr>
<tr>
<td>V/F (L)</td>
<td>339.7 (18.1)</td>
<td>360.3 (20.6)</td>
<td>306.2 (22.5)</td>
<td>314.1 (28.0)</td>
<td>391.6 (27.7)</td>
<td>560.4 (18.1)</td>
<td></td>
</tr>
</tbody>
</table>

For tmax, the median (minimum, maximum) values are presented.

For Cmax, the median (minimum, maximum) values are presented.

Dose-normalized exposures showed a decline as the dose increased, indicating a non-linear increase in all exposure parameters. However, these were within 2-fold for Cmax over the dose range 1 to 25 mg and for AUC24 over the dose range 1 to 75 mg. Statistical analyses of Cmax and AUCs (AUC24, AUCb, and AUCc) using a power model showed less than dose-proportional increase in the dose range of 1 mg to 225 mg following a single dose.

For repeated daily dose cohorts on both Day 1 and Day 7, the time course for mean plasma CVN424 concentrations following drug administration under fasted state appeared similar to that for the fasted single dose cohorts. Mean plasma CVN424 concentrations were detectable up to 72 hours post-dose following the last dose of CVN424 on Day 7.

Following a once-daily administration of CVN424 oral suspension for 7 days (Table 3), Cmax,ss, Cmin,ss, and AUC1ss increased with increase in dose in the 25 mg to 150 mg dose range. Mean plasma Cmax,ss values were 315 ng/mL, 776 ng/mL, and 1097 ng/mL, and Cmin,ss values were 74 ng/mL, 241 ng/mL, and 497 ng/mL for 25 mg, 75 mg, and 150 mg MAD cohorts, respectively. Mean plasma AUC1ss values on Day 7 were 2954 hours*ng/mL, 9425 hours*ng/mL, and 16,200 hours*ng/mL for 25 mg, 75 mg, and 150 mg MAD cohorts, respectively. Median Tmax ranged from 1.75 to 2.5 hours, and mean t1/2 ranged from 30.6 to 34.1 hours on Day 7 across MAD cohorts.

Point estimates of Cmax and AUCs (AUC24, AUCb) for both Day 1 and Day 7 using a power model suggest a less than dose-proportional increase in the dose range of 25 mg to 150 mg for MAD cohorts.

Mean plasma Cmax and AUC accumulation ratios ranged from 1.75 to 2.47 following once-daily dose of CVN424 oral suspension for 7 days across MAD cohorts, suggesting moderate accumulation of CVN424 as expected given the drug's half-life. Concentrations of CVN424 with once-daily dosing reached steady-state levels by Day 4 or 5.

### Safety and Tolerability

A summary of treatment emergent adverse events (TEAEs) is presented in Table 4. Overall, 6 of 40 subjects (15.0%) in the single-dose cohorts reported TEAEs during the study. Study drug-related TEAEs were reported by 2 of 40 subjects (5.0%) overall in the single-dose cohorts: 1 of 6 subjects each (16.7%) after receiving CVN424 75 mg (feeling hot) and 225 mg (headache).
No study drug-related TEAEs were reported by subjects after receiving CVN424 1 mg, 5 mg (fasted or fed conditions), or 25 mg or placebo.

Overall, 6 of 24 subjects (25.0%) in the multiple-dose cohorts reported TEAEs during the study. Study drug-related TEAEs were reported by 2 of 24 subjects (8.3%) overall in the multiple-dose cohorts: 1 of 6 subjects each (16.7%) while receiving CVN424 75 mg (dysphagia) and 150 mg (chills). No study drug-related TEAEs were reported by subjects while receiving CVN424 25 mg or placebo.

All TEAEs were mild in severity apart from one moderate TEAE of dysphagia in the 75 mg cohort, which was unrelieved by antacids or simethicone, and led to study drug discontinuation after Day 3 and early discontinuation from the study. The dysphagia resolved fully by study Day 7. No other subject

### Table 3
Mean (CV) plasma pharmacokinetic parameters of CVN424: multiple-dose cohorts

<table>
<thead>
<tr>
<th>Parameter (unit)</th>
<th>25 mg (N = 6)</th>
<th>75 mg (N = 6)</th>
<th>150 mg (N = 6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>C&lt;sub&gt;max&lt;/sub&gt; (ng/mL)</td>
<td>188.5 (29.2)</td>
<td>407.2 (30.7)</td>
<td>561.5 (23.2)</td>
</tr>
<tr>
<td>C&lt;sub&gt;max,ss&lt;/sub&gt; (ng/mL)</td>
<td>73.83 (26.7)</td>
<td>241.0 (41.6)</td>
<td>496.8 (35.9)</td>
</tr>
<tr>
<td>t&lt;sub&gt;max&lt;/sub&gt; (h)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1.750</td>
<td>2.000</td>
<td>2.008</td>
</tr>
<tr>
<td>AUC&lt;sub&gt;τ&lt;/sub&gt; (h*ng/mL)</td>
<td>(1.50, 3.00)</td>
<td>(1.50, 5.00)</td>
<td>(1.50, 3.00)</td>
</tr>
</tbody>
</table>

### Table 4
Summary of treatment emergent adverse events

<table>
<thead>
<tr>
<th>SAD Subjects</th>
<th>Placebo (N = 10)</th>
<th>1 mg (N = 6)</th>
<th>5 mg Fasted (N = 6)</th>
<th>5 mg Fed (N = 6)</th>
<th>25 mg (N = 6)</th>
<th>75 mg (N = 6)</th>
<th>225 mg (N = 6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any TEAE</td>
<td>2 (20.0)</td>
<td>1 (16.7)</td>
<td>0</td>
<td>1 (16.7)</td>
<td>0</td>
<td>1 (16.7)</td>
<td>1 (16.7)</td>
</tr>
<tr>
<td>Feeling hot</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1 (16.7)</td>
<td>0</td>
</tr>
<tr>
<td>Tooth abscess</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Dizziness</td>
<td>0</td>
<td>1 (16.7)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Headache</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1 (16.7)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Medical device site dermatitis</td>
<td>1 (10.0)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Tinea cruris</td>
<td>1 (10.0)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MAD Subjects</th>
<th>Placebo (N = 6)</th>
<th>25 mg (N = 6)</th>
<th>75 mg (N = 6)</th>
<th>150 mg (N = 6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any TEAE</td>
<td>0</td>
<td>3 (50.0)</td>
<td>1 (16.7)</td>
<td>2 (33.3)</td>
</tr>
<tr>
<td>Any TEAE Leading to Early Discontinuation</td>
<td>0</td>
<td>0</td>
<td>1 (16.7)</td>
<td>0</td>
</tr>
<tr>
<td>Medical device site dermatitis</td>
<td>0</td>
<td>1 (16.7)</td>
<td>0</td>
<td>1 (16.7)</td>
</tr>
<tr>
<td>Chills</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1 (16.7)</td>
</tr>
<tr>
<td>Back pain</td>
<td>0</td>
<td>1 (16.7)</td>
<td>0</td>
<td>1 (16.7)</td>
</tr>
<tr>
<td>Neck pain</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Dysphagia</td>
<td>0</td>
<td>0</td>
<td>1 (16.7)</td>
<td>0</td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>0</td>
<td>1 (16.7)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Headache</td>
<td>0</td>
<td>1 (16.7)</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>
reported dysphagia. There were no serious adverse effects or deaths reported, and no other subject discontinued early from the study. All TEAEs resolved by the end of the study.

No subject had a clinically significant abnormal vital sign. Body weight changes from baseline were similar across placebo and CVN424 cohorts. Modest elevations in body temperature and pulse rate were observed following administration of CVN424 (Fig. 3). These changes were detectable at 1 hour post-dose (the earliest scheduled post-dose assessment), increased further by 6 hours post-dose, and spontaneously returned to baseline by 24 hours post-dose. During the first 24 hours post-dose, the individual maximum observed temperature change from baseline was 1.6°C for CVN424 versus 0.8°C for placebo, and the maximum heart rate change from baseline was 57 beats per minute for CVN424 versus 33 beats per minute for placebo. These observations were restricted to the first dose of CVN424; elevations in temperature or other vital sign trends were not observed after administration of subsequent doses to the multiple-dose cohorts. Orthostatic vital sign changes were similar for CVN424 and placebo groups.

Discussion

The current standard of care for Parkinson’s disease is symptomatic treatment by dopamine replacement, dopamine agonists, or analogous mechanisms. After several years of treatment, many patients experience motor fluctuations that limit the effectiveness of those drugs and may also develop dyskinesias that are exacerbated by dopaminergic agents (e.g., levodopa-induced dyskinesias). Novel, non-dopaminergic therapies like CVN424 have potential to improve treatment of such patients.

This first-in-human study investigated the safety, tolerability, and PK of single and multiple escalating doses of CVN424 in healthy volunteers. CVN424 mean peak (C_max) and total (AUC_24, AUC_t, and AUC_\infty) plasma exposure increased with increase in CVN424 dose across the evaluated dose range (1–225 mg once daily, or 25–150 mg once daily for 7 days), although the increase appeared to be less than dose proportional. The food effect comparison showed a 33% reduction in C_max and a delay in t_max with food. A small increase in the overall exposure was noted when given with food (comparison of AUC_\infty, 19%), although AUC_24 and AUC_t values met equivalence criteria. Moderate plasma accumulation of CVN424 was observed following 7-day once daily dosing of CVN424 oral suspension, as expected given the drug’s half-life, with apparent steady-state concentrations of CVN424 being achieved following 4 or 5 days of dosing. The administration of CVN424 was safe and well tolerated and resulted in no serious adverse events. The only early discontinuation was for dysphagia (75 mg group), an adverse event not reported by any other subject.

Transient increases in temperature and heart rate, observed as first-dose effects, were not clinically significant in the study subjects. It is uncertain whether similar vital sign changes

![Fig. 3. (A) Mean (+/−S.D.) change from Baseline in Temperature. (B) Mean (+/−S.D.) change from baseline in pulse rate.](image-url)
will be observed in Parkinson’s disease patients, who may be elderly with various cardiac and autonomic co-morbidities and using concomitant medications. Curiously, the rise in heart rate averaged across all CVN424 cohorts was about 8 beats per minute per degree Celsius rise in temperature (data not shown), which is close to the 8.5 beats per minute physiologic rise in heart rate linked to each degree Celsius rise in febrile patients in previous studies (Karjalainen and Viitasalo, 1986). If that is not coincidental, perhaps CVN424 induces a temperature rise that indirectly leads to the increase in heart rate. An in vitro selectivity screen of CVN424 against 110 receptors, channels, and enzymes showed inhibition greater than 50% at 10 μM for adrenergic α1 receptors (maximum inhibition seen was 70% for α1D) and the sigma receptor (Brice et al., 2021), although it was not determined whether this inhibition in binding translates to a functional effect. The maximum total plasma concentration achieved in this trial was 1097 ng/ml (2.3 μM) at the top dose of the SAD cohort. Although adrenergic receptors are known to affect heart rate, it is unlikely that the free drug concentration was sufficient to modulate these receptors. Therefore, the mechanism by which CVN424 or modulation of GPR6 might cause the observed changes in vital signs is uncertain.

The data presented here detail the PK profile of a suspension formulation, while use of solid form in future clinical studies may require bridging PK analysis to assess bioequivalence.

While GPR6 expression is most prominent in striatal indirect pathway neurons, GPR6 expression has been observed in a subset of hypothalamic neurons in mice and humans (Henry et al., 2015; Cerevance unpublished data), which suggests a possible mechanism to account for our observations given the hypothalamus’s role in temperature and energy regulation and autonomic balance.

CVN424 is a non-dopaminergic compound that modulates a novel Parkinson’s disease therapeutic target. Previously published pre-clinical data has shown that CVN424 is efficacious in models relevant to Parkinson’s disease, such as the rat 6-OHDA lesion model, and achieves good levels of brain exposure with a total plasma concentration that achieves 50% receptor occupancy (RO50) of 7.4 ng/ml (Brice et al., 2021). In humans, CVN424 appears to be safe and well tolerated in healthy adults over a range that includes plasma exposures predicted from pre-clinical studies to achieve near saturation of GPR6 sites in the brain. These results supported the design of a phase II study of CVN424 adjunctive to levodopa in Parkinson’s disease patients with motor fluctuations, currently ongoing (NCT04191577).

Acknowledgments

The authors thank the volunteers who participated in the trial, as well as staff from PPD Development, including Carmichael Angeles, Yuansi Liu, Nancy Zheng, Bradley Wetzell, and Kristi Wheeler, who assisted in the conduct of the study and/or data analysis, James Woodworth, who assisted with data analysis, Mira Hong and colleagues at Frontage Laboratories, who developed and performed the PK analyses, and Ricardo Soto and Emily Marschok from Halloran Consulting Group, who assisted with operational oversight of study conduct. Natalie Hosea (Takeda Pharmaceutical Company) assisted with dose selection. At Cerevance, Andrew Aycough assisted with study drug manufacture and importation, Rob Middlebrook managed budgets and contracting, Lee Dawson provided comments on the manuscript, and Brad Margus provided strategic guidance. Nathaniel Heintz (Rockefeller U., Howard Hughes Medical Institute) provided critical insight into selection of GPR6 as a therapeutic target for Parkinson’s disease.

Authorship Contributions

Participated in research design: Margolin, Brice, Carlton.
Performed data analysis: Davidson, Margolin.
Wrote or contributed to the writing of the manuscript: Margolin, Brice, Matthews, Carlton, Davidson.

References


Address correspondence to: Mark Carlton, Cerevance, Ltd., 418 Cambridge Science Park, CB4 0PZ, Cambridge UK. E-mail: mark.carlton@cerevance.com